Primary angiosarcomas of the breast

被引:107
|
作者
Sher, Taimur
Hennessy, Bryan T.
Valero, Vicente
Broglio, Krisitine
Woodward, Wendy A.
Trent, Jonathan
Hunt, Kelly K.
Hortobagyi, Gabriel N.
Gonzalez-Angulo, Ana M.
机构
[1] Univ Texas, MD Anderson Canc Ctr, Dept Brest Med Oncol, Houston, TX 77030 USA
[2] Mt Sinai Med Ctr, Dept Internal Med, Miami Beach, FL 33140 USA
[3] Univ Texas, MD Anderson Canc Ctr, Dept Gynecol Oncol, Houston, TX 77030 USA
[4] Univ Texas, MD Anderson Canc Ctr, Dept Stat & Appl Math, Houston, TX 77030 USA
[5] Univ Texas, MD Anderson Canc Ctr, Dept Radiat Oncol, Houston, TX 77030 USA
[6] Univ Texas, MD Anderson Canc Ctr, Dept Sarcoma Med Oncol, Houston, TX 77030 USA
[7] Univ Texas, MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA
关键词
breast cancer; angiosarcoma; therapy;
D O I
10.1002/cncr.22784
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND. The purpose of the study was to describe the clinicopathologic characteristics and clinical outcomes of patients with primary breast angiosarcoma. METHODS. The institutional database was searched to identify breast angiosarcoma patients seen between 1965 and 2002. Survival outcomes were estimated by the Kaplan-Meier method. The log-rank test was used to compare groups. Cox proportional hazards models were used for multivariate analysis. RESULTS. In all, 69 patients were identified. Median follow-up was 40 months (range, 0-413 months). Median age was 46. Median tumor size at diagnosis was 5.5 cm. Thirteen (18.8%) patients received prior radiation for invasive breast carcinoma. Most patients underwent total mastectomy with (41%) or without (45%) axillary dissection. Regional metastasis to axillary lymph nodes was rare. There were 38 recurrences and 27 deaths. The 5-year overall (OS) and recurrence-free survival (RFS) rates were 61% (95% confidence interval [CI], 49%-76%) and 44% (95% CI, 33%-58%) with estimated medians of 100 and 37 months, respectively. In Cox proportional hazards models, OS and RFS were significantly associated only with T size and not with patient age, prior radiation, or chemotherapy administration. Of 29 patients treated with chemotherapy at recurrence, there were 4 complete and 10 partial responses (48%) with an anthracycline-ifosfamide or gemcitabine-taxane combination. CONCLUSIONS. Breast angiosarcoma is frequently advanced at diagnosis and has a tendency for local-regional recurrence. A significant number of responses to chemotherapy was observed in the metastatic setting. These data suggest that a multidisciplinary therapeutic approach should be employed in high-risk patients with large primary tumors.
引用
收藏
页码:173 / 178
页数:6
相关论文
共 50 条
  • [41] Primary angiosarcomas of the anterior mediastinum: A clinicopathologic and immunohistochemical study of 9 cases
    Weissferdt, Annikka
    Kalhor, Neda
    Suster, Saul
    Moran, Cesar A.
    HUMAN PATHOLOGY, 2010, 41 (12) : 1711 - 1717
  • [42] Complete radiographic response of primary pulmonary angiosarcomas following gemcitabine and taxotere
    Wilson, Rachel
    Glaros, Selina
    Brown, Richard K. J.
    Michael, Claire
    Reisman, David
    LUNG CANCER, 2008, 61 (01) : 131 - 136
  • [43] Angiosarcomas of Primary Gynecologic Origin A Clinicopathologic Review and Quantitative Analysis of Survival
    Kruse, Arnold-Jan
    Sep, Simone
    Slangen, Brigitte F. M.
    Vandevijver, Nathalie M.
    Van Gorp, Toon
    Kruitwagen, Roy F.
    Van de Vijver, Koen K.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2014, 24 (01) : 4 - 12
  • [44] Clinical significance of local control of primary tumour in definitive radiotherapy for scalp angiosarcomas
    Kashihara, Tairo
    Ogata, Dai
    Okuma, Kae
    Nakamura, Satoshi
    Nakayama, Hiroki
    Mori, Taisuke
    Takahashi, Akira
    Namikawa, Kenjiro
    Takahashi, Ayaka
    Takahashi, Kana
    Kaneda, Tomoya
    Inaba, Koji
    Murakami, Naoya
    Okamoto, Hiroyuki
    Nakayama, Yuko
    Yamazaki, Naoya
    Igaki, Hiroshi
    SKIN RESEARCH AND TECHNOLOGY, 2023, 29 (01)
  • [45] MYC amplification, TSC2, NSD1, TP53, and Tyrosine Kinase Mutations in Primary Breast Angiosarcomas
    Macedo, Rodrigo Tavares
    Duckworth, Lauren
    Rowe, J. Jordi
    Sciallis, Andrew
    Hashem, Sherin
    Dermawan, Josephine
    Moh, Michelle
    LABORATORY INVESTIGATION, 2024, 104 (03) : S277 - S278
  • [46] Taxanes in angiosarcomas
    Schlemmer, M.
    Reichardt, P.
    Verweij, J.
    Hartmann, J.
    Judson, I.
    Thyss, A.
    Hogendoorn, P. C. W.
    Marreaud, S.
    Van Glabbeke, M.
    EJC SUPPLEMENTS, 2009, 7 (02): : 66 - 66
  • [47] Cutaneous angiosarcomas
    Fink-Puches, R
    Smolle, J
    Beham, A
    Kerl, H
    Soyer, HP
    HAUTARZT, 2000, 51 (07): : 479 - 485
  • [48] Primary and secondary angiosarcomas of the liver: a multi-institutional study of 32 cases
    Liao, Xiaoyan
    Lai, Jinping
    Lin, Jingmei
    Zhang, Dongwei
    HUMAN PATHOLOGY, 2023, 137 : 10 - 17
  • [49] HEPATIC ANGIOSARCOMAS
    SABRIA, M
    REY, C
    RUBIESPRAT, J
    ORTEGA, A
    ALOMAR, C
    SANS, M
    MEDICINA CLINICA, 1981, 76 (02): : 52 - 56
  • [50] Angiosarcomas and taxanes
    Penel N.
    Lansiaux A.
    Adenis A.
    Current Treatment Options in Oncology, 2007, 8 (6) : 428 - 434